Abstract
Background and Objectives
As blood collection agencies (BCAs) seek to increase donor diversity, making changes to eligibility criteria to enable more people to donate is an important consideration. BCAs in Canada have a permanent deferral from whole blood and platelet donation for anyone with a history of malaria, a barrier to donation for many in African, Caribbean and Black (ACB) communities. If a malaria nucleic acid test (NAT) is implemented in donor screening, malaria‐related deferral criteria could be eased. This study explored the public's views on potential changes to malaria deferral criteria.
Materials and Methods
A mixed‐methods community‐based study was conducted in Canada. This paper reports results from the qualitative component (n = 26). Topics explored in semi‐structured interviews included experiences with donation, awareness and knowledge of deferral criteria, cognitive interview questions and potential responses to receiving a positive test result for malaria.
Results
Participants understood blood donor screening processes as a shared responsibility of both BCAs and donors for ensuring blood safety. Participants had a literal interpretation of donor screening questions assessed, and most would feel comfortable answering the questions in a blood donation context. If malaria NAT is implemented and they were to receive a positive test result, participants shared they would respond with concern, fear and uncertainty.
Conclusion
If BCAs work to implement a malaria NAT and ease deferral criteria, this must be communicated clearly and effectively to the public and donors, with particular focus on communities impacted. BCAs should work with community partners to communicate these changes.
Keywords: blood donations, cognitive interviews, donor screening, malaria deferral, qualitative methods
Highlights.
The general public understands donor screening processes are vital for ensuring blood safety and a shared responsibility of blood collection agencies and donors.
Screening questions that may be used for testing should malaria nucleic acid test (NAT) be implemented (e.g., questions related to residency in a malaria‐endemic region and history of malaria) are understandable.
Implementing malaria NAT and easing malaria deferral criteria should be accompanied by a strong communication strategy to mitigate uncertainty, confusion and potential negative responses.
INTRODUCTION
Blood collection agencies (BCAs) implement donor screening questionnaires and testing to maintain the safety of the blood supply. Screening questionnaires and deferral criteria, however, may also have significant social and behavioural impacts on donors. Literature exploring behavioural impacts of temporary and permanent deferral criteria shows deferrals can cause lower rates of return among certain groups such as younger donors, those with less experience with blood donation, women and racialized people, compared to older donors, those with more experience with blood donation, men and non‐racialized people [1]. Studies further show donors experience negative emotions when they are deferred [2].
Malaria deferral criteria are applied in blood donor screening to reduce the risk of transfusion‐transmitted infections, with different countries having different criteria. In Canada, BCAs have a permanent deferral for whole blood and platelet donation for anyone with a history of malaria and a 3‐year deferral for residency in a malaria‐endemic country. Although transfusion‐transmitted malaria is a recognized risk with the potential to cause morbidity, the incidence in many non‐endemic countries is low [3]. Malaria deferral criteria also disproportionately impact donors from malaria‐endemic regions [4], including many in African, Caribbean and Black (ACB) communities [5, 6]. Deferral criteria that function as a barrier to donation for ACB communities are not only experienced as discriminatory [6] but also pose a challenge to BCAs' efforts to increase the genetic diversity of their blood donor pool to support meeting the needs of all patients, especially those living with sickle cell disease [7]. As such, sickle cell organizations, including Sickle Cell Disease Association of Canada (SCDAC), have been advocating for easing malaria deferral criteria while maintaining the safety of the blood supply. Canadian Blood Services (CBS)—one of two BCAs in Canada—states on its website it is evaluating the implementation of a recently licensed malaria nucleic acid test (NAT) in donor screening with the aim to ease these deferral criteria [7]. If the submission for this change is approved by Health Canada, the regulator, removal of the lifetime deferral for a history of malaria will address a significant barrier to donation for ACB communities [8].
For BCAs that rely on voluntary donation, it is critical to assess public awareness and understanding regarding potential changes to screening criteria. To date, public awareness of donor screening criteria, including malaria screening criteria, remains under‐researched.
MATERIALS AND METHODS
This study builds on a collaborative research partnership between SCDAC and CBS and applies a community‐based participatory research approach whereby community partners share in the decision‐making and guide the research [9]. Over the years, SCDAC has advocated for increasing donations from ACB communities to increase the genetic diversity of the blood donor base to better support the needs of people living with sickle cell disease. This current study applied a mixed‐methods design including both a national survey [10] and qualitative interviews. The survey aimed to assess knowledge of blood donation and deferral criteria and examine views on changes and potential changes to eligibility criteria, including potential malaria‐related changes. The qualitative interviews aimed to generate more in‐depth insights on potential changes to malaria‐related deferral criteria to inform potential implementation of malaria NAT in donor screening and easing of malaria‐related donor deferral criteria. Research ethics approvals were obtained from CBS (REB#2024.017) and the University of Alberta (Pro00135834).
Participant recruitment
Interview participants (n = 26) were recruited from survey participants. Surveys were distributed across Canada by community organizations and through personal and professional networks of the research team. In total, a recruitment email and poster were sent to over 100 organizations. Participants who completed the survey (n = 385) were invited to participate in an interview to explore in‐depth topics related to the malaria deferral criteria. From those participants who indicated interest, people from high malaria endemic regions were prioritized (although not exclusively invited to participate in an interview) since we anticipated they were most likely to be impacted should malaria NAT be implemented and malaria deferral criteria changed.
Eligibility criteria included 17 years and older (age of consent for blood donation), residing in Canada and comfortable communicating in English. Participants were not required to have experience donating blood or knowledge of BCAs or malaria to participate in the study. Participants received a $25 e‐gift card.
Data collection and analysis
Interviews were 30–60 min and conducted from January–June 2025 using the video‐conferencing platform Zoom (Version 6.3.0). Topics explored included experiences with donation (if any), awareness and knowledge of deferral criteria, cognitive interview questions and potential reactions to receiving a positive test result for malaria.
Cognitive interviewing is a qualitative data collection method designed to assess understanding and interpretation of specific questions used in a questionnaire. Its purpose is to highlight problems that might arise within a questionnaire and has the broad aim of determining how participants may come to their answers or responses [11]. Cognitive interview questions aimed to gain insights into participants' understanding (including any need for clarification) and comfort/discomfort with potential questions that could be used in selective testing for malaria.
Interviews were audio‐recorded, transcribed and de‐identified for analysis. Transcripts were coded in NVivo, with descriptive and thematic analysis conducted [11]. JH and CJ read through several transcripts and developed the codebook, which included both deductive (categories informed by interview questions) and inductive codes (categories identified through a close reading of the transcripts). Code reports were further reviewed and analysed to identify themes and patterns [12].
RESULTS
Most participants identified as women (n = 20, 76.9%), with six men. The age range was 19 to 67 years. Participants were from Ontario, Manitoba, Saskatchewan, Alberta and British Colombia (see Table 1 for participant characteristics). Half the participants had no prior donation experience, often for reasons such as being deferred from donating, lack of interest or competing social responsibilities (n = 13). Of the remaining 13, most had experience donating in Canada (n = 8, 62%) and the remaining had experience donating abroad (n = 5, 38%). Participants who had experience donating blood described the experience in positive ways, often referring to the process as ‘pleasant’. Most participants had experience with deferrals through direct experience (i.e., return donors and temporary deferrals); however, at least two participants experienced deferrals as first time donors resulting in their lack of donation experience. Others heard of deferrals second‐hand or through education (n = 7, 27%). Only four (15%) participants were not aware of deferrals. Those who had firsthand experience had been deferred because of being underweight, medication, low haemoglobin and tattoos. At least one participant explained they were a regular donor who had self‐deferred for malaria following travel to a malaria‐endemic region.
TABLE 1.
Participant characteristics.
| Gender | Woman = 20 (77%) | Man = 6 (23%) | |||||
| Age (years) | 17–29 = 10 (38%) | 30–39 = 11 (42%) | 40–49 = 4 (15%) | 50–60+ = 1 (4%) | |||
| Ethnicity | Black/African/Caribbean = 15 (58%) | Mixed/multi‐ethnic = 3 (12%) | South Asian = 3 (12%) | Southeast Asian = 2 (8%) | Middle Eastern = 1 (4%) | White/European = 1 (4%) | Latino/Latina = 1 (4%) |
| Residence | British Columbia = 1 (4%) | Alberta = 11 (42%) | Saskatchewan = 1 (4%) | Manitoba = 6 (23%) | Ontario = 7 (27%) | ||
| Generational status | First generation = 19 (73%) | Second generation = 6 (23%) | Third, or more, generation = 1 (4%) | ||||
Cognitive interview questions
At the time of the study, four questions in the donor screening questionnaire were under consideration to be used for selective donor testing and therefore were asked in the cognitive interview component.
Q1: Were you born outside Canada or the United States? If yes, where were you born?
Q2: In the last 3 months, did you return from a stay of less than 6 months outside Canada or the United States? If yes, where did you go?
Q3: In the last three and a half years, have you spent more than 6 months in a continuous period outside Canada or the United States? If yes, where did you stay?
Q4: Have you ever had malaria?
Q1: Birthplace question
Understanding
All participants had a literal understanding of this question, and most said they understood the importance of Q1 within a healthcare context. Phrasing the question as ‘outside Canada or the United States’, however, led a few participants to seek clarity regarding why there was a need to identify these two countries over other low‐malaria endemic regions. This led some participants to be concerned about whether they would be questioned further depending on their response. For example, one participant shared:
If you're from Canada or the U.S., then you're fine. If not, then [the blood operator] needs to investigate further? Just be neutral, ask where were you born (P24, African/Black/Caribbean, first generation).
Other participants wondered if this phrasing suggests that diseases found in other countries were a concern for the blood operator. Finally, some participants associated the question with ideas of nationality and citizenship, or being an ‘outsider’.
Comfort
All participants said they would be comfortable answering Q1 in donor screening. Some explained they would be comfortable because they were born in Canada or the United States. Still, many described an awareness and sensitivity to how the question could be interpreted by others who have not been born in Canada, suggesting some may feel the question is ‘exclusionary’. Other participants wondered if people not born in Canada might feel uncomfortable answering because it could be interpreted as categorizing people into groups that are more or less desirable.
Q2: Travel question
Understanding
Most participants understood Q2 to be asking about short‐term travel with the aim of identifying whether they had been exposed to infectious agents while abroad. Specific to blood donation, some participants explicitly related travel and infection concern to diseases that could be spread through blood donation, with a few expressing an understanding that travel can lead to different rates of exposure to infections or disease. As one participant explained:
Maybe there's some viral thing going around in some places. I know some places have different [healthcare] practices. Maybe they want to know if I contracted them or got treatment for anything (P15, African/Black/Caribbean, first generation).
Many participants that associated Q2 with travel and exposure to different infections situated this within an understanding that BCAs and donors work together to ensure safety of the blood supply:
[CBS] wants to make sure the sample I'm giving is safe to use. I also want to be clear I'm not a risk and I'm not posing any difficulties for those using the sample (P14, African/Black/Caribbean, first generation).
For most participants, COVID‐19 normalized travel‐specific questions which they applied to the context of blood donation.
Comfort
While all participants understood the importance of asking Q2 in blood donation screening and most would feel comfortable answering this question, a few expressed some discomfort with recall, especially if they travel frequently. As many participants understood Q2 aims to assess health risk and exposure, this led some participants to wonder how necessary questions about travel are if donations are tested. Others wondered if travel to some countries might be considered more ‘desirable’ or ‘right’ than others. Finally, some reflected on whether it was necessary to consider not only the duration and destination of travel, but activities completed during travel, reasons for travel or contact with individuals since these could influence exposure and infection risk.
Q3: Residency question
Understanding
Almost all participants associated Q2 and Q3 as related to one another, adding both questions were intended to ascertain a donor's possible exposure to disease through time spent in specific regions. Most participants understood Q3 to be asking about residency instead of travel, which made some more concerned about privacy and information sharing. A few participants wanted clarification on why the BCA needed to know about residency and how their answers would be stored and shared, if at all. For example, one participant wondered if BCA data are shared with state organizations responsible for citizenship:
I start thinking about Immigration, Refugee and Citizenship Canada. I'm wondering, are you talking to each other? (P06, South Asian, first generation).
Another participant noted that in some provinces, if someone is out of the country for more than 6 months, they lose healthcare coverage; therefore, answers to the residency question may have implications if provincial health agencies have access to BCA data. While BCAs in Canada do not share this information with provincial public health, participants were not aware of this.
Comfort
Despite some questions and concerns, almost all participants said that they would feel comfortable answering Q3 within the context of blood donation. Many explained that they expect BCAs to ask questions as part of the procedures for maintaining the safety of the blood supply. Participants further situated their level of comfort within the framing of public health and safety, which contributed to feeling comfortable answering Q3. Some participants felt it was important to clarify how the information was going to be used and who would have access to it. Finally, some noted they were ‘reassured’ by this question and others because it demonstrated the measures that the BCA was taking to support the safety of the blood supply.
Q4: Malaria question
Understanding
Most participants expressed some level of knowledge of the relationship between malaria and blood donation. While information on malaria and blood donation was provided in the survey that all interview participants completed prior to their interview, most participants explained their previous place of birth or residence, or family history, had contributed to their knowledge of the relationship between malaria and blood donation. As one participant shared:
I'm from Africa. I know mosquitoes cause it and it affects your blood. If I'm going to donate blood, then my blood should be free from malaria parasites (P24, African/Black/Caribbean, first generation).
While all participants had a literal interpretation of Q4, many raised the need for some clarification. Participants from malaria‐endemic regions explained that since malaria exposure is widespread in some regions, like a ‘seasonal disease’, further clarification is needed about what is meant by ‘having had malaria’. They wondered if the question was asking about presentation of symptoms and self‐diagnosis was sufficient, or if a confirmatory test is needed. Some asked if having had malaria meant being treated and/or hospitalized. While many participants from malaria‐endemic regions interpreted Q4 as associated with eligibility criteria, they questioned whether this could result in a deferral since some of them had not previously been deferred for a history of malaria in their country of origin.
Comfort
Though most participants said they would feel comfortable answering this question in a blood donation questionnaire and explained they understood that asking about a history of malaria is to ‘safeguard blood’ some also described feelings of discomfort. Some of this discomfort was because participants with a history of malaria or from malaria‐endemic regions had different experiences with BCAs in their country of origin. These experiences informed their knowledge about risk, donation and malaria. For example, one participant explained:
Almost everyone in Nigeria has had malaria; it's so common. I don't think it would be a disqualifying factor for blood donation (P09, African/Black/Caribbean, first generation).
While most participants thought it was important to ask about history of malaria, participants who had malaria or were from malaria‐endemic regions shared that inclusion of Q4 may potentially lead donors to feel excluded based on previous infection. Still others were not certain if having had malaria would prevent them from donating. Several participants who were either born in or travelled to regions where malaria is prevalent believed that to reduce feelings of discomfort and confusion, BCAs could provide greater details when donors schedule appointments about the relationship between malaria, testing and deferral.
Positive result notification
Participants were asked how they might react if they were to receive a positive malaria test result following a donation if a malaria NAT is implemented in blood donation screening. Some referred to previous experiences of receiving a positive test result as informing their response to receiving a positive test for malaria. Participants' reactions to a positive malaria result were nuanced and at times reflected tensions with different emotions. Most participants explained this would bring a mix of emotions at once, such as surprise, fear, stress and confusion. Several participants acknowledged their reactions would change depending on factors such as previous diagnosis, travel history, recent travel experiences, contact with other travellers and/or known possible exposure related to residency or birth.
Fear and surprise/uncertainty
Almost all participants agreed they would feel fear if they received notification of a positive result for malaria, particularly if they lacked symptoms. Many participants expressed that it would be ‘extremely scary’ whereas a few others explained they would feel more ‘surprise, maybe uncertainty’. One participant noted:
I think that would be scary for me because I have kind of a fear of not knowing. I would be wondering how long I have had it and if that affects treatment (P03, African/Black/Caribbean, second generation).
Many participants agreed that even though they would be ‘pretty scared’ they would ‘rather know’ than not. Often participants' reactions were influenced by their exposure to and experience with malaria. Participants who were less familiar with malaria explained they would feel a mixture of emotions. For example, one participant shared:
Malaria is a big deal. I could be wrong, but I think I've heard once you get it, you never really get rid of it (P02, African/Black/Caribbean, second generation).
Participants from malaria‐endemic regions described their reactions as being influenced by factors such as how many years they had lived in Canada, whether they had recently travelled and time of last diagnosis of malaria. These factors further influenced how they viewed malaria and their potential worries about a positive test result. This led many to wonder about the relationship between timeframe of exposure, and NAT testing sensitivity, and how this may impact test results. One participant wondered:
I've been here for like 2 years. I'm not sure I should have anything in my system still showing malaria (P16, African/Black/Caribbean, first generation).
At least one participant from a malaria‐endemic region said it would feel ‘traumatizing’ to learn that she had malaria after being outside of her country of origin for several years.
Stress, anxiety, and disappointment
Many participants explained that reactions of fear were also closely intertwined with other negative reactions such as stress, anxiety and disappointment. Some participants with less malaria experience explained that their reactions of stress, anxiety and disappointment were because they had no exposure to malaria and limited knowledge of its impact on health. One participant explained:
I'd probably feel stressed, I don't really know what malaria is (P25, Middle Eastern, first generation).
Many participants with more knowledge and experience of malaria shared that they would be disappointed to be notified, less because of their own health concerns and more because of concerns about being ‘disqualified’ from donating blood. Other participants wondered whether any factors, such as receiving treatment for malaria, might change a donor's eligibility. Some participants from malaria‐endemic regions also expressed they would feel ‘bad’ if they received a positive test result and would ‘probably advise everyone not to donate blood, especially if they're Nigerian or have been exposed to malaria before’ (P09, African/Black/Caribbean, first generation) since this might mean they are ineligible to donate.
Most participants, regardless of their experience with malaria, explained their negative reactions were less about being notified that they tested positive and more about the uncertainty of what a positive result means and potential difficulties in accessing healthcare. One participant shared:
There are walk‐in clinics here, but they're always busy. I'd definitely be stressed about what to do (P02, African/Black/Caribbean, second generation).
Participants further expressed worry about a positive test result and what it means in terms of treatment and long‐term health impacts.
DISCUSSION
Our findings suggest that participants understand blood donor screening processes as vital for ensuring blood safety and a shared responsibility of both BCAs and donors. COVID‐19 normalized answering travel questions and, for some, normalized receiving positive test results. Participants expressed understanding of the donor screening questions assessed in the study, and most would feel comfortable answering the questions in a blood donation context. Results suggest that even for people who are not regular or current blood donors, they bring their understanding of the role of BCAs to their interpretation of the screening questions. This aligns with findings of donors' interpretation of potential sexual behaviour−based questions in the questionnaire [12], and that donors answer screening questions based on their interpretation of the question [6, 13].
Alongside participants' comfort with the questions assessed, they raised important questions for BCAs to consider. Notably, participants' responses to Q1 (birthplace) and Q4 (malaria) suggest BCAs should consider providing clarity with these questions. In the current socio‐political context, questions about birthplace are often associated with ideas of citizenship or belongingness, which may raise concerns for some. BCAs should consider explaining why questions about birthplace are asked, how this information will be used and how the data will be shared with other organizations. Clarity on what is meant by ‘having had malaria’ would also help decrease uncertainty, especially for those who have some experience with malaria. BCAs should communicate to the public and donors whether this question is asking about a confirmatory test, presentation of symptoms and/or treatment for malaria. Lastly, BCAs should clearly communicate what a positive test for malaria means and its impact on donor eligibility.
Participants' responses of concern regarding the potential to receive a positive test result for malaria are consistent with other studies that show donors may misunderstand positive result notification, have trouble recalling details about exposure, and need guidance from healthcare professionals in understanding health impacts [14]. Our results also underscore the need for BCAs to offer clear information on how to interpret the positive result notification, clarification of how the testing was done, and what the result means for their health. In particular, people who have had experience with malaria and test positive would be notably surprised and concerned if they are asymptomatic. For these potential donors, it is imperative that BCAs provide clear information about how it is possible to test positive for the parasite while asymptomatic, and what this means for their health and future donations. Guiding donors on where and when they should seek healthcare is also recommended, especially in countries where malaria is non‐endemic. Participants explained that they were not confident that their doctor would know how to treat malaria given that it is not a common infection in Canada. BCAs should address these concerns in their communication to donors who test positive for malaria.
It is necessary to ensure clear and effective communication of any changes to malaria deferral criteria to the public and donors (including clarification of screening questions, reasons for the change, testing process and impacts of a positive test result), with particular focus on communities impacted. Research shows that changes to deferral criteria are not often communicated effectively to people and communities that may be newly eligible to donate [15] and that communities historically excluded from blood donation would prefer to hear about changes from trusted people [16]. BCAs should work with community groups to ensure that information is communicated in a clear and meaningful way. Moreover, communication of these changes to internal staff and expanding training is necessary to ensure that donors are welcomed and questions are addressed appropriately.
Our study was limited to hearing from people on their reflections of how they may be impacted by potential changes to the malaria deferral criteria. Because the malaria NAT has not yet been implemented, participants were asked to consider how they might respond to donor questionnaires and notifications of positive testing results. While this line of questioning can provide useful information to BCAs as they plan to implement this change, how people think they might respond may differ from their actual response. We recommend a follow up study after implementation of the assay to assess impact on donors when receiving a positive test result to inform BCAs.
In conclusion, addressing systemic barriers to donation for ACB communities and enabling their full participation is vital to supporting the healthcare needs of everyone, especially those affected by sickle cell disease. SCDAC has been a key partner in working towards the removal of the malaria deferral criteria change and raising awareness for the importance of blood donation in ACB communities. BCAs should continue to work with community partners, such as SCDAC, as they work to address barriers to donation and diversify the donor base.
CONFLICT OF INTEREST STATEMENT
The authors declare no conflicts of interest.
ACKNOWLEDGEMENTS
This research received funding support from Canadian Blood Services. The views herein do not necessarily reflect the views of Canadian Blood Services.
C.J. contributed to data collection and analysis, writing—original draft and writing—review and editing. C.C. contributed to conceptualization of the project and writing—reviewing and editing. J.K. contributed to writing—reviewing and editing. B.T. contributed to conceptualization of the project and writing—reviewing and editing. J.H. contributed to conceptualization of the project, data collection and analysis, writing—original draft, writing—reviewing and editing, project administration and funding acquisition.
DATA AVAILABILITY STATEMENT
Data supporting this study cannot be made available due to ethical restrictions.
REFERENCES
- 1. Davison TE, Masser BM, Gemelli CN. Deferred and deterred: a review of literature on the impact of deferrals on blood donors. ISBT Sci Ser. 2020;15:3–10. [Google Scholar]
- 2. Whittaker S, Carter N, Arnold E, Shehata N, Webert KE, Distefano L, et al. Understanding the meaning of permanent deferral for blood donors. Transfusion. 2008;48:64–72. [DOI] [PubMed] [Google Scholar]
- 3. O'Brien SF, Ward S, Gallian P, Fabra C, Pillonel J, Kitchen AD, et al. Malaria blood safety policy in five non‐endemic countries: a retrospective comparison through the lens of the ABO risk‐based decision‐making framework. Blood Transfus. 2019;17:94–102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Cheng Q, Hoad VC, Bentley P, Harley R, Schenberg K, Wiseman V. Optimal malarial screening strategy in Australian blood donors: a cost‐effectiveness analysis. Vox Sang. 2024;119:936–944. [DOI] [PubMed] [Google Scholar]
- 5. Haw J, Walrond J, Jayachandran J, Dordunoo D, Eche‐Ameh H, Muwhen U, et al. Sickle cell disease and the need for blood: barriers to donation for African, Caribbean, and Black young adults in Canada. Transfusion. 2023;63:1324–1332. [DOI] [PubMed] [Google Scholar]
- 6. Haw J, Senga J, Dordunoo D, Tinga B. Systemic barriers to donation for African, Caribbean and Black communities: a qualitative key informant study. Transfusion. 2026;63:1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Canadian Blood Services . Malaria and blood donation. Available from: https://www.blood.ca/en/blood/am-i-eligible-donate-blood/malaria. Last accessed 13 Mar 2026.
- 8. Canadian Blood Services: Canadian Blood Services seeks Health Canada approval to introduce new screening test for malaria. Available from: https://www.blood.ca/en/about‐us/media/newsroom/canadian‐blood‐services‐seeks‐health‐canada‐approval‐introduce‐new. Last accessed 27 Jul 2026.
- 9. Haw J, Anagnostopoulos G, Kotadia A, Li A, Mclean D, Morakinyo T, et al. Recruiting under‐represented racialized young adults to the stem cell registry: how we applied a community‐engaged research approach and lessons learned. JPRM. 2025;6:1–22. [Google Scholar]
- 10. Kasongo N, Jennie H, Courtney J, Biba T, Carmen C. Public awareness and knowledge of blood donation eligibility and deferral criteria: fostering a culture of donation and advancing equity. Transfusion. 2026. 10.1111/trf.70336 [DOI] [PubMed] [Google Scholar]
- 11. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77–101. [Google Scholar]
- 12. Willson S, Miller K, Seem D, Kuehnert MJ. Cognitive evaluation of the AABB Uniform Donor History Questionnaire. Transfusion. 2016;56:1662–1667. [DOI] [PubMed] [Google Scholar]
- 13. Braun V, Clarke V. Successful qualitative research: a practical guide for beginners. London: SAGE Publications; 2013. [Google Scholar]
- 14. Öhrner C, Kvist M. How do blood donors interpret the Swedish donor history questionnaire? ISBT Sci Ser. 2018;13:123–130. [Google Scholar]
- 15. O'Brien SF, Naicker K, Osmond L, Holloway K, Drews SJ, Bigham M, et al. Notification of blood donors who test positive for transfusion‐transmissible infections. Vox Sang. 2025;120:394–400. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Woo H, Fisher W, Kohut T, Haw J. Qualitative analysis of Canadian blood and plasma donors' views on expanding donor screening eligibility for gay, bisexual, and other men who have sex with men. Transfusion. 2024;64:85–92. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data supporting this study cannot be made available due to ethical restrictions.
